Speaker at Global Conference on Pharmaceutics and Drug Delivery Systems 2018 - Sergey Bachurin
Russian Academy of Sciences, Russian Federation
Title : The main trends in the developing novel therapeutics for alzheimer’s disease treatment

Abstract:

Alzheimer’s disease (AD) is characterized by a chronic and progressive neurodegenerative process resulting from the intracellular and extracellular accumulation of fibrillary proteins: beta-amyloid and hyperphosphorylated Tau. Over accumulation of these aggregates leads to synaptic dysfunction and subsequent neuronal loss. The precise molecular mechanisms of AD are still not fully understood but it is clear that AD is a multifactorial disorder and that advanced age is the main risk factor. Over the last decade more than 50 drug candidates have successfully passed phase II clinical trials, but none have passed phase III. Here, we summarize data on current “anti-Alzheimer’s” agents currently in clinical trials based on findings available in the Thomson Reuters «Integrity» database, on the public website www.clinicaltrials.gov, and on database of the website Alzforum.org. As a result, it was possible to outline some major trends in AD drug discovery: 1) the development of compounds acting on the main stages of the pathogenesis of the disease – the so-called “disease-modifying agents”. These drugs could potentially slow the development of structural and functional abnormalities in the CNS providing sustainable improvements of cognitive functions, which persist even after drug withdrawal. 2) Focused design of multitargeted drugs acting on multiple molecular targets involved in the pathogenesis of the disease. 3) Finally, the repositioning of old drugs for new (“anti-Alzheimer’s”) application, offers a very attractive approach to facilitate the completion of clinical trials [Bachurin S. et al., Med.Res.Rev.,(2017). 37(5):1186-1225].

Biography:

Bachurin Sergey has completed his PhD and Dr. Sci. Degree in Moscow State University, Russia. In 1992 and in 1995 he had been working in the University San Francisco and in Taft’s University (USA). Since 2006 he is a director of the Institute of Physiologically Active Compounds, Russian Academy of Science in Chernogolovka, Russia, and the Head of Department of Medicinal and Biological Chemistry. He has published more than 220 papers in reputed journals and about 40 patents, and has been serving as an editorial board member of repute.

Watsapp